Policosanol: Updating and perspectives

Mediterranean Journal of Nutrition and Metabolism

Volumn 1, Issue 2, 2008, Pages 77-83

  Viola, Franca ^a   Oliaro, Simona ^a   Binello, Arianna ^a   Cravotto, Giancarlo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Clinical studies; High molecular weight alcohols; Hypocholesterolaemic; Policosanol

Indexed keywords

EID: 85013615580     PISSN: 1973798X     EISSN: 19737998     Source Type: Journal    
DOI: 10.3233/s12349-008-0019-y     Document Type: Article

References (78)

1. 2 assimilation. Plant Physiol, 79: 357-364.
2. Lesniak AP, Haug A, Ries SK (1986). Stimulation of ATPase in barley (Hordeum vulgare) root plasma membrane after treatment of intact tissues and cell free extracts with triacontanol. Physiol Plant, 68: 20-26.
3. McBride PT, Clark I, Krueger GG (1987). Evaluation of triacontanol-containing compounds as anti-inflammatory agents using guinea-pig models. J Invest Dermatol, 89: 380-383.
4. Saint-John M, McNaughton L (1986). Octacosanol ingestion and its effects on metabolic responses to submaximal cycle ergometry, reaction time and chest and grip strength. Int Clin Nutr Rev, 6: 81-87.
5. Norris FH, Denys EH, Fallat RJ (1986). Trial of octacosanol in amyotrophic lateral sclerosis. Neurology, 36: 1263-1264.
6. Sho H, Chinen I, Fukuda N (1984). Effects of Okinawan sugar cane wax and fatty alcohol on serum and liver lipids in the rat. J Nutr Sci Vitamin, 30: 553-559.
7. Shimura S, Hasegawa T, Takano S, Suzuki T (1987). Studies on the effect of octacosanol on motor endurance in mice. Nutr Rep Intern, 36: 1029-1036.
8. Hernández F, Illnait J, Más R et al (1992). Effects of policosanol on serum lipids and lipoproteins in healthy volunteers. Curr Ther Res, 51: 568-575.
9. Pons P, Rodríguez M, Robaina C et al (1994). Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharm Res, 14: 27-33.
10. Aneiros E, Más R, Calderón B et al (1995). Effect of policosanol in lowering-cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res, 56: 176-182.
11. Castaño G, Más R, Fernández L et al (2000). Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol, 13: 187-195.
12. Más R, Castaño G, Illnait J et al (1999). Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther, 65: 439-447.
13. Pons P, Rodríguez M, Más R et al (1994). One-year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res, 55: 1084-1092.
14. Canetti M, Morera M, Illnait J et al (1995). A two years study on the efficacy and tolerability of policosanol in patients with type II. Int J Clin Pharm Res, 15: 159-165.
15. Ortensi G, Gladstein H, Valli H, Tesone PA (1997). A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res, 58: 390-401.
16. Benítez M, Romero C, Más R et al (1997). A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia. Curr Ther Res, 58: 859-867.
17. Castaño G, Más R, Arruzazabala ML et al (1999). Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res, 19: 105-116.
18. Crespo N, Illnait J, Mas R et al (1999). Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Int J Clin Pharm Res, 19: 117-127.
19. Castaño G, Menéndez R, Más R et al (2002). Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated to type 2 diabetes mellitus. Int J Clin Pharm Res, 22: 89-100.
20. Marcello S, Gladstein J, Tesone P, Mas R (2000). Effects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: a pilot study. Curr Ther Res, 61: 346-357.
21. Castaño G, Fernández L, Mas R et al (2003). Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation on patients with dyslipidemia and type 2 diabetes mellitus. Clin Drug Invest, 23: 639-650.
22. Arruzazabala ML, Valdés S, Más R et al (1996). Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res, 34: 181-185.
23. Carbajal D, Arruzazabala ML, Valdés S, Más R (1998). Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids, 58: 61-64.
24. Arruzazabala ML, Molina V, Mas R et al (2002). Antiplatelet effects of policosanol 20 and 40 mg/d in healthy volunteers and dyslipidemic patients. Clin Exp Pharmacol Physiol, 29: 891-897.
25. Arruzazabala ML, Más R, Molina V et al (1998). Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tiss React, 20: 119-124.
26. Menéndez R, Más R, Amor AM et al (2000). Effects of policosanol treatment on the susceptibility of low-density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol, 50: 255-262.
27. Menéndez R, Más R, Amor A et al (2000). Effects of policosanol on the low density lipoprotein (LDL) isolated on hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation. A randomised, double-blinded pilot study. Curr Ther Res, 61: 609-620.
28. Menéndez R, Fernández I, del Río A et al (1994). Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res, 27: 199-203.
29. Menéndez R, Amor A, Rodeiro I et al (2001). Policosanol modulates HMGCoA reductase activity in cultured fibroblasts. Arch Med Res, 32: 8-12.
30. Menéndez R, Arruzazabala ML, Más R et al (1997). Cholesterollowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Br J Nutr, 77: 923-932.
31. Menéndez R, Amor AM, González RM et al (1996). Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats. Biol Res, 29: 253-257.
32. Castaño G, Más R, Fernández L et al (1998). A double-blind placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology, 50: 123-130.
33. Castaño G, Mas R, Fernández L et al (2001). A long-term study of policosanol in the treatment of intermittent claudication. Angiology, 52: 115-125.
34. Castaño G, Más R, Gámez R et al (2003). Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study. Angiology, 55: 361-371.
35. Fernández L, Más R, Illnait J et al (1998). Policosanol: results of a postmarketing surveillance control on 27879 cases. Curr Ther Res, 59: 717-722.
36. Más R, Rivas P, Izquierdo JE et al (1999). Pharmaco-epidemiologic study of policosanol. Curr Ther Res, 60: 458-467.
37. Más R (2000). Policosanol. Drugs Future, 25: 569-586.
38. González Canavaciolo VL, Magraner Hernández J (1999). Validation of a gas chromatographic method for determining fatty alcohols that compose policosanol in five-milligram film-coated tablets. J AOAC Int, 82: 834-839.
39. Sierra R, González V, Magraner J (2002). Validation of a gas chromatographic method for determination of fatty alcohols in 10 mg film-coated tablets of policosanol. J AOAC Int, 85: 563-566.
40. Gouni-Berthold I, Berthold HK (2002). Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J, 143: 356-365.
41. McCarty MF (2002). Policosanol safely down-regulates HMGCoA reductase-potential as a component of the Esselstyn regimen. Med Hypotheses, 59: 268-279.
42. Pepping J (2003). Policosanol. Am J Health Syst Pharm, 60: 1112-1115.
43. Chen JT, Wesley R, Shamburek RD et al (2005). Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy, 25: 171-183.
44. Arruzazabala ML, Valdés S, Más R et al (1997). Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res, 36: 293-297.
45. Stuart MJ, Gerrard JM, White JG (1980). Effect of cholesterol on production of thromboxane b2 by platelets in vitro. New Engl J Med, 302: 6-10.
46. Lacoste L, Jules YT et al (1995). Hyperlipidemia and coronary disease. Circulation, 92: 3172-3177.
47. Wang YW, Jones PJ, Pischel I, Fairow C (2003). Effects of policosanols and phytosterols on lipid levels and cholesterol biosynthesis in hamsters. Lipids, 38: 165-170.
48. Kassis AN, Jones PJ (2006). Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons. Am J Clinl Nutr, 84: 1003-1008.
49. Kassis AN, Marinangeli CP, Jain D et al (2007). Lack of effect of sugar cane policosanol on plasma cholesterol in Golden Syrian hamsters. Atherosclerosis, 194: 153-158.
50. Lin Y, Rudrum M, van der Wielen RP et al (2004). Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism, 53: 1309-1314.
51. Dulin MF, Hatcher LF, Sasser HC, Barringer TA (2006). Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr, 84: 1543-1548.
52. Berthold HK, Unverdorben S, Degenhardt R et al (2006). Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia. A randomized controlled trial. JAMA, 295: 2262-2269.
53. Cubeddu LX, Cubeddu RJ, Heimowitz T et al (2006). Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. Am Heart J, 152: 982.e1-982.e5.
54. Greyling A, De Witt C, Oosthuizen W, Jerling JC (2006). Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolemic and heterozygous familial hypercholesterolemic subjects. Br J Nutr, 95: 968-975.
55. Castano G, Fernandez L, Mas R et al (2005). Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. Drugs R D, 6: 207-219.
56. Castano G, Mas R, Fernandez L et al (2005) A comparison of the effect of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study. Drugs Exp Clin Res 31[Suppl]: 31-44
57. Wright CM, Zielke JC, Whayne TF (2004). Policosanol, an aliphatic alcohol sugarcane derivative: use in patients intolerant or inadequately responsive to statin therapy. Int J Angiol, 13: 173-175.
58. Cicero AF, Rovati LC, Setnikar I (2007). Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung, 57: 26-30.
59. Reiner Z, Tedeschi-Reiner E, Romic Z (2005). Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and Creactive protein in hypercholesterolaemic patients. Clin Drug Investig, 25: 701-707.
60. Irmak S, Turgut N, Milligan J (2006). Policosanol contents of beeswax, sugar cane and wheat extracts. Food Chem, 95: 312-318.
61. Borg J (1991). The neurotrophic factor, n-hexacosanol, reduces the neuronal damage induced by the neurotoxin, kainic acid. J Neurosci Res, 29: 62-67.
62. Azzouz M, Kennel PF, Warter JM et al (1996). Enhancement of mouse sciatic nerve regeneration by the long chain fatty alcohol n-hexacosanol. Exp Neurol, 138: 189-197.
63. Mas R (2001). D-002. Drugs Future, 26: 731-744.
64. Carbajal D, Molina V, Valdés S et al (1998). Anti-inflammatory activity of D-002: an active product isolated from beeswax. Prostaglandins Leukot Essent Fatty Acids, 59: 235-238.
65. Carbajal D, Molina V, Valdés S et al (1995). Anti-ulcer activity of higher primary alcohols of beeswax. J Pharm Pharmacol, 47: 731-733.
66. Carbajal D, Molina V, Valdés S et al (1996). Possible cytoprotective mechanism in rats of D-002 an anti-ulcerogenic product isolated from beeswax. J Pharm Pharmacol, 48: 858-860.
67. Menéndez R, Amor AM, González RM et al (2000). Inhibition of rat microsomal lipid peroxidation by the oral administration of D-002. Braz J Med Biol Res, 33: 85-90.
68. Molina V, Valdés S, Carbajal D et al (2001). Antioxidant effects of D-002 on gastric mucosa of rats with injury induced experimentally. J Med Food, 4: 79-83.
69. Menéndez R et al (1998) Antioxidant effects of D-002 on healthy volunteers. Data on file, Dalmer, Havana City, Cuba
70. Castaño G, Fernández L, Mas R et al (2002). Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia. Int J Clin Pharmacol Res, 22: 55-66.
71. Setnikar I, Senin P, Rovati LC (2005). Antiatherosclerotic efficacy of policosanol, red yeast rice extract and astaxanthin in the rabbit. Arzneimittelforschung, 55: 312-317.
72. Ng CH, Leung KY, Huang Y, Chen ZY (2005). Policosanol has no antioxidant activity in human low-density lipoprotein but increases excretion of bile acids in hamsters. J Agric Food Chem, 53: 6289-6293.
73. Luo C-M, Shu X-M (2006). Mechanism of action and clinical research of policosanol. Zhongguo Yaowu Yu Linchuang, 6: 607-611.
74. Majeed M, Prakash L, Jayaram J (2007). A double-blind study to evaluate the safety and efficacy of policosanol vs. atorvastatin in the treatment of hyperlipidemia. Nutracos, 6: 16-19.
75. Prat H, Roman O, Pino E (1999). Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia. Rev Med Chil, 127: 286-294.
76. Goldstein JL, Brown MS (1990). Regulation of the mevalonate pathway. Nature, 343: 425-430.
77. Singh DK, Li L, Porter TD (2006). policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther, 318: 1020-1026.
78. Ferrer A, Caelles C, Massot N, Hegardt FG (1985). Activation of rat liver cytosolic 3-hydroxy-3-methylglutaryl coenzyme A reductase kinase by adenosine 5-monophosphate. Biochem Biophys Res Commun, 132: 497-504.